May 30, 2018
BBI Solutions has released four new antibodies specific for the HIV-1 p24 capsid protein. The antibodies are the first evidence of BBI using the internal antibody custom service expertise gained through the acquisition of Maine Biotechnology Services, to develop products for their reagent suite. Having a combined team of antibody and assay development specialists allowed BBI to select antibodies from a large pool of candidates screened with IVD customer applications in mind.
Read More
May 09, 2018
For 25 years Precision BioLogic’s CRYOcheck™ range of fresh frozen plasma reagents, calibrators and controls have provided cost savings and improved patient care, with faster, more accurate results for your laboratory.
Read More
May 08, 2018
8th May 2018: Oxford & Manchester, UK and Atlanta, GA. Cytox, a precision medicine testing company which today is commercializing polygenic risk scoring (PRS) and other approaches for assessing genetic risk for developing Alzheimer’s disease, has collaborated with integrated genomics and genetics leader AKESOgen to verify the performance of the Cytox genoBAR™ test with saliva samples.
Read More
Apr 26, 2018
Faecal Immunochemical Testing (FIT) is now an established diagnostic test that identifies the presence of minute quantities of haemoglobin (blood) in the stool, known as faecal occult blood (FOB), which can be an early sign of colorectal cancer. FIT uses antibodies specific to human haemoglobin so is more sensitive and has a greater specificity than the previous qualitative guaiac based methods.
Read More
Apr 26, 2018
Alpha Laboratories Ltd. (Eastleigh, UK) is delighted to have been appointed as the exclusive distributor for Arquer Diagnostics Ltd (“Arquer”) in the UK and Republic of Ireland. Arquer (Sunderland, UK) is an in-vitro diagnostic company developing breakthrough diagnostic tests for the detection of bladder and prostate cancer.
Read More
Apr 24, 2018
Germantown, Maryland, and Hilden, Germany, April 20, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSure®, which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.
Read More
Apr 20, 2018
SYDNEY, AUSTRALIA – (April 19, 2018). SpeeDx’s ResistancePlus® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company’s recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company – SpeeDx Pty Ltd – as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the ResistancePlus MG assay.*
Read More
Apr 17, 2018
Espoo, Finland, April 17th, 2018 - Mobidiag, a Finnish molecular diagnostics company, today announced the launch of Novodiag® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currentl...
Read More
Mar 20, 2018
Oxford developed prognostic assay for risk of post-surgical recurrence in Stage II colorectal cancer patients to be available throughout China
Read More
Mar 19, 2018
Northampton, UK – 20th March 2018 – HORIBA UK Ltd, Medical announces that in a study recently undertaken and published as a case study by the Oxford Academic Health Science Network (AHSN), its Microsemi CRP point-of-care (POC) analyser was found to enable more rapid clinical decision-making, saving time and reducing costs, in emergency paediatric units.
Read More
Page 1 of 7 FirstPrevious [1]